Drug Trial Radar · NCT06882057
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Last checked: Nov 20, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Mar 3, 2025
Primary completion
Dec 31, 2029
Study completion Jun 2033
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CCCG-ALL2025 LR-B-ALL plan is designed based on the CCCG-ALL2020 plan. This is a clinical trial using 14 days of blinatumomab (Blina-14) as early intensification after induction therapy and 2nd Blina-14 in consolidation therapy in all newly diagnosed provisional low-risk (LR) pediatric acute lymphoblastic leukemia (ALL) patients, regardless of measurable residual diseases (MRD) status. We will compare the efficacy of chemotherapy combined with Blina-14, comparing to CAT+ intensification or historical regimens. Patients with early remission in depth will receive chemo-light late intensification and maintenance therapy afterwards. Early complete remission in depth and maintenance reduction will be determined by next-generation sequencing (Ig-NGS MRD).
Conditions
- Acute Lymphoblastic Leukemia ALL
- Childhood Leukemia, Acute Lymphoblastic
- B Cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions
BlinatumomabDrug
All LR-B-ALL patients will be treated with 14 days of blinatumomab (Blina-14) as early intensification to replace CAT+ (historically given in LR-B-AL with MRD19\>0.1% in the 2020 protocol). Additionally, second 14 days of blinatumomab will be given after completion of HDMTX consolidation treatment.
Reinduction-2 omissionDrug
Reinduction-2 will be omitted for patients with NGS-MRD46\<10\^-6 who have receive the two courses of Blina-14.
Chemo-light Maintenance 2Drug
Patients with FCM-MRD19\<0.01% and IgH rearrangement NGS MRD 46\<10\^-6 will receive chemo-light maintenance-2 with 4 cyles of 8-week course of MTX + 6MP (totally 32 weeks).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare 3-year event-free survival (EFS) between patients who receive Blina-14 intensification with this historical controls from CCCG-ALL2015 and CCCG-ALL2000Time frame: The expected study duration is approximately 5 years.
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
Anhui Medical University Second Affiliated Hospital
Hefei, Anhui, China · Not yet recruiting
Anhui Provincial Children's Hospital
Hefei, Anhui, China · Not yet recruiting
Chongqing Medical University Affiliated Children's Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Not yet recruiting
Guangzhou Women and Children's Medical Center
Guangzhou, Guangdong, China · Not yet recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
The People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China · Not yet recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Not yet recruiting
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Wuhan Children's Hospital
Wuhan, Hubei, China · Not yet recruiting
Hunan Children's Hospital
Changsha, Hunan, China · Not yet recruiting
The Third Xiangya Hospital of the Central South University
Changsha, Hunan, China · Not yet recruiting
Xiangya Hospital Central South University
Changsha, Hunan, China · Not yet recruiting
Nanjing Children's Hospital Affiliated to Nanjing Medical University
Nanjing, Jiangsu, China · Not yet recruiting
Children's Hospital of Soochow University
Suzhou, Jiangsu, China · Not yet recruiting
Jiangxi Provincial Children's Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Not yet recruiting
Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Not yet recruiting
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanghai Children's Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanghai Children's Medical Cener, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Not yet recruiting
Xi'an Northwest Women and Children Hospital
Xi’an, Shanxi, China · Not yet recruiting
Shenzhen Children's Hospita
Shenzhen, Shenzhen, China · Not yet recruiting
West China Second University Hospital
Chengdu, Sichuan, China · Not yet recruiting
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Tianjin, Tianjin Municipality, China · Recruiting
Hong Kong Children's Hospital
Hong Kong, Hong Kong, Hong Kong · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.